SCHEDULE: Bain Capital Life Sciences Reduces Stake in NewAmsterdam Pharma

Bain Capital Life Sciences entities sold 4.8 million NewAmsterdam Pharma shares for $168.4 million, reducing their collective beneficial ownership to approximately 6.4%.

Summary

• Bain Capital Life Sciences entities, including BCLS II Investco, BCLS Fund II, and BCIPLS, sold a total of 4,800,000 Ordinary Shares of NewAmsterdam Pharma Company N.V.
• The shares were sold at a price of $35.10 per share in a privately negotiated block transaction.
• The aggregate consideration for the sale was $168.4 million.
• Following the transaction, the reporting persons collectively beneficially own approximately 6.4% of the outstanding Ordinary Shares, including shares issuable upon exercise of warrants and pre-funded warrants.
• This ownership is based on 113,390,804 Ordinary Shares outstanding as of October 31, 2025, plus 1,732,652 Ordinary Shares issuable from warrants.

Sentiment

Score: 4

Explanation: The significant reduction in stake by a major institutional investor, while at a good price, generally signals a less positive outlook or a strategic exit, which can create downward pressure or uncertainty for the stock.

Positives

• The sale was executed at a significant price of $35.10 per share, indicating a strong valuation for the shares sold.
• The transaction generated substantial aggregate consideration of $168.4 million for the selling entities.

Negatives

• A significant reduction in stake by a major institutional investor like Bain Capital Life Sciences could be interpreted by the market as a decrease in confidence or a strategic portfolio rebalancing away from the issuer.

Future Outlook

NA

Industry Context

This transaction reflects a portfolio adjustment by a major life sciences investor, Bain Capital, within the biotechnology and pharmaceutical sector. While specific industry trends are not detailed, such a significant sale by a specialized fund often indicates either a realization of gains, a strategic shift in investment focus, or a response to specific company performance or market conditions within the biopharma space.

Stakeholder Impact

• Shareholders: May experience increased selling pressure or uncertainty due to the large block sale by a major investor. The sale price of $35.10 per share could set a reference point for valuation.

Key Dates

Recommendation

While a major institutional investor has significantly reduced its stake, the sale was executed at a robust price of $35.10 per share, indicating a healthy valuation. This could be a portfolio rebalancing rather than a vote of no confidence. Investors should hold and monitor future developments, including the company's operational performance and any further insider/institutional ownership changes, before making a definitive buy or sell decision.

Keywords

NewAmsterdam Pharma, Bain Capital Life Sciences, Schedule 13D/A, share sale, block trade, institutional ownership, biotechnology, pharmaceuticals, equity, investor activity